143 related articles for article (PubMed ID: 35497888)
1. Hearing Impairments as an Overlooked Condition in Kidney Transplant Recipients.
Simsir M; Yildiz MG; Karatas M; Dalgic A; Ozturk I; Tatar E; Eren N; Erken E; Gungor O; Altunoren O
Transpl Int; 2022; 35():10198. PubMed ID: 35497888
[TBL] [Abstract][Full Text] [Related]
2. Sudden hearing loss associated with tacrolimus after pediatric renal transplant.
Gulleroglu K; Baskin E; Bayrakci U; Aydin E; Ozluoglu L; Moray G; Haberal M
Exp Clin Transplant; 2013 Dec; 11(6):562-4. PubMed ID: 24344948
[TBL] [Abstract][Full Text] [Related]
3. Hearing Status in Pediatric Renal Transplant Recipients.
Gulleroglu K; Baskin E; Aydin E; Ozluoglu L; Moray G; Haberal M
Exp Clin Transplant; 2015 Aug; 13(4):324-8. PubMed ID: 25365361
[TBL] [Abstract][Full Text] [Related]
4. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients.
Naicker D; Reed PW; Ronaldson J; Kara T; Wong W; Prestidge C
Pediatr Nephrol; 2017 Nov; 32(11):2125-2131. PubMed ID: 28660366
[TBL] [Abstract][Full Text] [Related]
5. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
6. Colchicine levels in chronic kidney diseases and kidney transplant recipients using tacrolimus.
Amanova A; Kendi Celebi Z; Bakar F; Caglayan MG; Keven K
Clin Transplant; 2014 Oct; 28(10):1177-83. PubMed ID: 25125128
[TBL] [Abstract][Full Text] [Related]
7. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
[TBL] [Abstract][Full Text] [Related]
8. Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic review.
Braithwaite HE; Darley DR; Brett J; Day RO; Carland JE
Transplant Rev (Orlando); 2021 Apr; 35(2):100610. PubMed ID: 33756310
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
10. Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients.
Mei T; Noguchi H; Suetsugu K; Hisadome Y; Kaku K; Okabe Y; Masuda S; Nakamura M
Biol Pharm Bull; 2020; 43(10):1600-1603. PubMed ID: 32999170
[TBL] [Abstract][Full Text] [Related]
11. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
12. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus Metabolite M-III May Have Nephrotoxic and Myelotoxic Effects and Increase the Incidence of Infections in Kidney Transplant Recipients.
Zegarska J; Hryniewiecka E; Zochowska D; Samborowska E; Jazwiec R; Borowiec A; Tszyrsznic W; Chmura A; Nazarewski S; Dadlez M; Paczek L
Transplant Proc; 2016 Jun; 48(5):1539-42. PubMed ID: 27496443
[TBL] [Abstract][Full Text] [Related]
14. Maternal, Decidual, and Neonatal Lymphocyte Composition Is Affected in Pregnant Kidney Transplant Recipients.
Feyaerts D; Gillard J; van Cranenbroek B; Rigodanzo Marins L; Baghdady MMS; Comitini G; Lely AT; van Hamersvelt HW; van der Heijden OWH; Joosten I; van der Molen RG
Front Immunol; 2021; 12():735564. PubMed ID: 34777345
[TBL] [Abstract][Full Text] [Related]
15. Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study.
Bussalino E; Marsano L; Parodi A; Russo R; Massarino F; Ravera M; Gaggero G; Fontana I; Garibotto G; Zaza G; Stallone G; Paoletti E
J Nephrol; 2021 Apr; 34(2):531-538. PubMed ID: 32533451
[TBL] [Abstract][Full Text] [Related]
16. Investigation of hearing loss in patients with acute brucellosis by standard and high-frequency audiometry.
Kaygusuz TO; Kaygusuz I; Kilic SS; Yalcin S; Felek S
Clin Microbiol Infect; 2005 Jul; 11(7):559-63. PubMed ID: 15966974
[TBL] [Abstract][Full Text] [Related]
17. Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients.
Griffin SP; Nelson JE
Prog Transplant; 2016 Dec; 26(4):314-321. PubMed ID: 27628498
[TBL] [Abstract][Full Text] [Related]
18. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
